JonesTrading
James O'Neill has a diverse and extensive work experience in the investment banking industry. Currently, they hold the position of Managing Director and Co-Head of Healthcare Investment Banking & Head of Healthcare ECM at JonesTrading since September 2023.
Prior to this, they worked at Oppenheimer & Co. Inc. where they held various roles, including Head of Healthcare Equity Capital Markets from February 2021 to October 2022, Managing Director Investment Banking from February 2020 to September 2022, and Executive Director Investment Banking from April 2017 to February 2020.
Before joining Oppenheimer & Co. Inc., James worked at Roth Capital Partners as part of their Equity Capital markets team from July 2012 to March 2017. James also served as Vice President at Rodman & Renshaw from August 2010 to July 2012, Vice President at Cantor Fitzgerald from June 2009 to August 2010, and was involved in Equity Sales & Trading at Dahlman Rose & Co. (Acquired by Cowen Group, Inc.) from January 2005 to June 2009.
James O'Neill attended Manhattan College but did not complete a degree or specify a field of study.
This person is not in any offices
JonesTrading
JonesTrading is one of the oldest and largest executing equity trading firms in the U.S. and is a worldwide leader in equity block trading. Since 1975, the sole focus of JonesTrading has been creating liquidity for institutional and corporate clients on an unconflicted basis. The ability to provide a secure, trusted platform connecting a diverse group of market players enables the firm to unlock liquidity, providing best-quality execution for larger and more complex trades. JonesTrading has been a trusted, high touch execution partner for institutional money managers and hedge funds for over 40 years. We understand the intricacies of execution and the importance of anonymity. Through our network of over 100 registered representatives we source liquidity from over 1,500 institutions and hedge funds in addition to virtually every exchange and dark pool. We are able to secure advantageous prices across the greatest number of markets in a timely manner, without revealing client intent. We remain neutral and clients remain anonymous, minimizing market impact and opportunity costs. Refer to the Firm's website ("Our Companies") for relevant disclosures: https://www.jonestrading.com/